Table 1.
Demographic and Preoperative Outcomes
| Variables | Total Stentless Valve Replacement | Age | p-value* | |||
|---|---|---|---|---|---|---|
| <40 | 40–59 | 60–74 | ≥75 | |||
| (n=1947) | (n=105) | (n=528) | (n=860) | (n=454) | ||
| Gender (female) | 606 (31) | 30 (29) | 121 (23) | 263 (31) | 192 (42) | <0.001 |
| Pre-existing Comorbidities | ||||||
| Hypertension | 1240 (64) | 30 (29) | 269 (51) | 603 (70) | 338 (74) | <0.001 |
| Diabetes Mellitus | 352 (18) | 5 (5) | 62 (12) | 192 (22) | 93 (21) | <0.001 |
| CAD | 753 (39) | 4 (3.8) | 125 (24) | 380 (44) | 244 (54) | <0.001 |
| CHF | 889 (46) | 54 (51) | 235 (45) | 389 (45) | 211 (47) | 0.599 |
| COPD | 328 (17) | 10 (9.5) | 60 (11) | 177 (21) | 81 (18) | <0.001 |
| Renal Failure on Dialysis | 30 (1.5) | 3 (2.9) | 9 (1.7) | 17 (2) | 1 (0.2) | 0.055 |
| BAV | 719 (37) | 70 (67) | 285 (54) | 284 (33) | 80 (18) | <0.001 |
| Marfan Syndrome | 13 (0.7) | 1 (1) | 9 (1.7) | 3 (0.3) | 0 (0) | 0.0039 |
| LVEF | 0.004 | |||||
| >60% | 709 (36) | 32 (30) | 181 (34) | 322 (37) | 174 (38) | |
| 40–60% | 972 (50) | 60 (57) | 275 (52) | 430 (50) | 207 (45) | |
| 20–40% | 191 (9.8) | 8 (7.6) | 53 (10) | 75 (8.7) | 55 (12) | |
| <20% | 75 (3.9) | 5 (4.8) | 19 (3.6) | 33 (3.8) | 18 (4.0) | |
| Previous Cardiac Surgery | ||||||
| AV Replacement | 148 (7.6) | 17 (16) | 46 (8.7) | 70 (8.1) | 15 (3.3) | <0.001 |
| AV Repair | 22 (1.1) | 9 (8.6) | 11 (2.1) | 1 (0.1) | 1 (0.2) | <0.001 |
| Aortic Root Replacement | 53 (2.7) | 6 (5.7) | 23 (4.4) | 18 (2.1) | 6 (1.3) | 0.004 |
| Ascending Aorta or Arch Replacement | 28 (1.4) | 2 (1.9) | 17 (3.2) | 6 (0.7) | 3 (0.7) | 0.001 |
| CABG | 164 (8.4) | 1 (1.0) | 26 (4.9) | 92 (11) | 45 (9.9) | <0.001 |
Data presented as median (25 %, 75 %) for continuous data and n (%) for categorical data. P-value < 0.05 defined as statistically significant difference between the four age groups. Abbreviations: AV, aortic valve; Asc, BAV, bicuspid aortic valve; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
*:
After Bonferroni correction, p<0.003 was considered significant.